Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seasonique

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

Patently unclear?

The challenge of protecting  biotech innovations

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Macron, Merkel and May: implications of the 2017 elections for the life science industry

Political instability and policy continuity in Europe’s biggest economies mean a worsening commercial environment stacked with uncertainty

Teva’s Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

- PMLiVE

Teva offloads women’s health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

- PMLiVE

FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links